A deviation investigation into a papered-over problem with a tablet press was so inadequate that the US Food and Drug Administration sent a warning letter about it to the company, Indoco Remedies Ltd., Mumbai, India.
The 16 July warning letter reflects two of FDA’s enforcement priorities: strong data integrity and thorough investigations.







